How to Understand Your Mesothelioma Pathology Report

Step 1: Understand What a Pathology Report Is

A pathology report is a laboratory document created after a pathologist, a physician who specializes in diagnosing disease by examining tissue samples, reviews cells obtained from your biopsy. During a biopsy, a small sample of tissue is removed from the suspected tumor and sent to the pathology laboratory for analysis.

The pathologist examines your tissue under a microscope, performs specialized staining tests, and issues a written report that describes what was found. This report is the definitive document that confirms a mesothelioma diagnosis. It is more conclusive than imaging studies alone, because it provides direct evidence of the cancer cells themselves.

Your pathology report will typically include the specimen type (where the biopsy was taken from), a gross description (what the tissue looked like to the naked eye), a microscopic description (what was seen under the microscope), the final diagnosis, and the results of any special tests performed. Understanding each of these sections gives you a complete picture of your diagnosis.

Step 2: Identify the Mesothelioma Type and Location

Your pathology report will specify where the mesothelioma originated, which is classified by the membrane it developed in. This information is fundamental because the location of the disease determines which treatment approaches are available and influences prognosis.

Pleural mesothelioma develops in the lining of the lungs (the pleura) and accounts for approximately 75% of all mesothelioma cases. It is the most extensively studied form, and patients have the widest range of treatment options, including surgery, chemotherapy, immunotherapy, and radiation.

Peritoneal mesothelioma develops in the lining of the abdomen (the peritoneum) and accounts for roughly 20% of cases. Treatment often involves a combination of cytoreductive surgery and heated intraperitoneal chemotherapy (HIPEC), which has shown encouraging survival outcomes at specialized centers.

Pericardial mesothelioma (lining of the heart) and testicular mesothelioma are both extremely rare, each representing less than 1-2% of diagnoses. Treatment options for these types are more limited, and care at a specialized center is especially important.

Step 3: Learn Your Cell Type

Cell type, also called histological subtype, is one of the most important pieces of information in your pathology report. It describes what the cancer cells look like under the microscope and is one of the strongest predictors of how the disease will behave and respond to treatment.

Epithelioid mesothelioma is the most common cell type, accounting for approximately 70% of all diagnoses. Epithelioid cells tend to grow more slowly and respond better to treatment than other cell types. Patients with epithelioid mesothelioma generally have the most favorable prognosis and the widest range of treatment options, including eligibility for aggressive surgical approaches.

Sarcomatoid mesothelioma accounts for roughly 10-15% of diagnoses. These cells are more irregular in shape, grow more aggressively, and are more resistant to standard treatments. Sarcomatoid mesothelioma typically has a less favorable prognosis, though newer immunotherapy combinations have shown some promise for this cell type.

Biphasic mesothelioma, which accounts for the remaining 15-20% of cases, contains a mixture of both epithelioid and sarcomatoid cells. The prognosis for biphasic mesothelioma depends largely on the ratio of the two cell types. A tumor that is predominantly epithelioid behaves more like epithelioid mesothelioma, while one that is predominantly sarcomatoid tends to be more aggressive.

Step 4: Understand Staging Information

Your pathology report may include staging information, though a complete stage determination often requires additional imaging studies beyond what the biopsy alone can provide. Staging describes how far the cancer has spread and is critical for determining treatment options.

Mesothelioma staging uses the TNM system. The T component describes the size and extent of the primary tumor, including whether it has grown into nearby structures. The N component indicates whether cancer has spread to nearby lymph nodes. The M component indicates whether the cancer has metastasized to distant parts of the body.

These three components combine into an overall stage of I through IV. Stage I mesothelioma is localized, meaning the tumor is confined to the membrane where it originated. Patients with Stage I disease typically have the most treatment options, including potentially curative surgery. Stage II and III indicate progressive local spread, with increasing involvement of nearby tissues and lymph nodes. Stage IV indicates that the cancer has spread to distant organs.

If your pathology report does not include complete staging information, your oncologist will determine your stage based on a combination of the pathology findings and imaging studies such as CT scans, PET scans, and MRI. The stage is a starting point for treatment planning, not a definitive prediction of outcome.

Step 5: Review Immunohistochemistry Results

Your pathology report will likely include results from immunohistochemistry (IHC) testing. These are specialized staining tests that help pathologists confirm the mesothelioma diagnosis and distinguish it from other cancers that can look similar under the microscope, particularly lung adenocarcinoma.

Immunohistochemistry works by applying antibodies that bind to specific proteins expressed by different types of cancer cells. The pattern of positive and negative results creates a diagnostic profile. For mesothelioma, pathologists look for a characteristic combination of markers.

Common positive markers for mesothelioma include calretinin, which is expressed in the majority of epithelioid mesothelioma cases; WT-1 (Wilms Tumor 1), another marker frequently positive in mesothelioma; D2-40, a lymphatic marker commonly expressed in mesothelial cells; and CK5/6, a cytokeratin marker. Your report may also note that certain markers associated with other cancers, such as CEA, TTF-1, or MOC-31, were negative, which helps rule out lung cancer and other diagnoses.

You do not need to memorize these markers. The important takeaway is that IHC testing provides additional diagnostic certainty. If your report shows a clear pattern of mesothelioma-positive markers and the absence of markers associated with other cancers, the diagnosis is well-supported.

Step 6: Discuss Your Report with Your Oncologist

A pathology report is a technical document, and interpreting it in the context of your individual situation is the role of your oncologist. Schedule a dedicated appointment to review the report in detail rather than trying to understand it entirely on your own.

Bring specific questions. Ask your oncologist to explain your cell type and what it means for your treatment options. Ask how your stage affects the treatment plan and whether you are a candidate for surgery, chemotherapy, immunotherapy, or a combination. If anything in the report is unclear, ask for a plain-language explanation.

Ask whether a second pathology opinion is warranted. Mesothelioma is difficult to diagnose, and pathologists without extensive mesothelioma experience can sometimes misclassify the cell type or confuse mesothelioma with other cancers. If your biopsy was reviewed at a general hospital pathology department, having the slides sent to a pathologist who specializes in mesothelioma can provide additional confidence. Learn more in our guide on getting a mesothelioma second opinion in the diagnosis and ensure the cell type classification is accurate.

Remember that your pathology report is also a critical legal document. It provides the medical confirmation of your diagnosis that is required to pursue a mesothelioma lawsuit or file asbestos trust fund claims. Keep copies of all pathology materials in a secure location, and provide them to your attorney when you begin the legal process.